Results 151 to 160 of about 153,965 (262)

Implementation of Polish guidelines on futile therapy protocols in pediatric intensive care units: a multicenter retrospective review. [PDF]

Sci Rep
Damps M, Rybojad B, Byrska-Maciejasz E, Gajda M, Mierzewska-Schmidt M, Bartkowska-Śniatkowska A, Zielińska M, Kubica-Cielińska A, Pągowska-Klimek I, Aftyka A, Wiktor Ł, Duda I.   +11 more
europepmc   +1 more source

Infusion rate adjustment in enzyme replacement therapy with pabinafusp alfa for mucopolysaccharidosis II

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Enzyme replacement therapy (ERT) for mucopolysaccharidosis II (MPS II) requires long‐term, weekly intravenous infusions often lasting over 3 h each time, which can burden paediatric patients and caregivers and negatively affect their quality of life and treatment compliance.
Kimitoshi Nakamura, Norio Sakai, Hideaki Hirai, Naoko Takasao, Ryo Ibaraki, Tatsuyoshi Yamamoto, Yuji Sato   +6 more
wiley   +1 more source

Use of lorazepam for analgosedation during mechanical ventilation in pediatric intensive care. [PDF]

Front Med (Lausanne)
Healy P, Marano M, Montibeller M, Goffredo BM, Pontrelli G, Della Pasqua O.   +5 more
europepmc   +1 more source

Identification of antibiotic allergies in children using prescribing patterns in the electronic medical record

British Journal of Clinical Pharmacology, EarlyView.
Background By age three, 5%–75% of children have a documented antibiotic allergy (AL). Despite this prevalence, recognition remains low because of limited clinician knowledge and time. Our study evaluates a novel approach to identifying AL using electronic medical record (EMR) prescription patterns.
Georgia Koutsaplis, Kailey Tang, Renee Dimond, Alice Lei, Amanda Wilkins, Amanda Gwee   +5 more
wiley   +1 more source

Use of preload responsiveness tests in pediatric intensive care units: A nationwide prospective clinical practice analysis. [PDF]

Ann Intensive Care
Gotchac J, Lecomte A, Belaroussi Y, Bourgoin P, Denante S, Klifa R, Perdreau E, San Geroteo J, Brissaud O, Gavotto A, Amedro P, FRAICHE Study Group Groupe Francophone de Réanimation et d’Urgences Pédiatriques (GFRUP).   +11 more
europepmc   +1 more source

Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Canagliflozin was recently approved in type 2 diabetes mellitus (T2DM) patients ≥10 and <18 years old as a single agent dosed once daily (QD) or in a fixed‐dose combination with metformin dosed twice daily (BID). We characterize canagliflozin pharmacokinetics in paediatric patients with T2DM, compare estimated individual and simulated ...
Nele Goeyvaerts, Per Olsson Gisleskog, Martine Neyens, Juan José Perez Ruixo, Saberi Rana Ali, Iolanda Cirillo, Oliver Ackaert   +6 more
wiley   +1 more source

RSV bronchiolitis versus COVID-19: could pediatric intensive care units have done more during the pandemic? [PDF]

BMC Pediatr
Hansen G, Holt T.
europepmc   +1 more source

Case‐malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy

British Journal of Clinical Pharmacology, EarlyView.
Aim Many women take medications during pregnancy. However, the risk to the fetus from most medications is uncertain. Congenital anomalies are one of the leading causes of infant death and contribute to long‐term disability. Signal detection methods can be used to systematically identify possible medication–anomaly associations that require further ...
Hannah Johnson, Helen Dolk, Maria Loane, Christine Damase‐Michel, Joanne Given, Hedvig Nordeng, Jorieke E. H. Bergman, Iain Carey, Elly Den Hond, Ester Garne, Florence Rouget, Lea Bruneau, Isabelle Monier, Anke Rissmann, Mary O'Mahony, Miriam Gatt, Renée Lutke, Joanna Sichitiu, Elisa Ballardini, Alessio Coi, Clara Cavero Carbonell, David Tucker, Joan Morris   +22 more
wiley   +1 more source

Artificial Intelligence in Predicting Mortality Risk for Critically Ill Children in Pediatric Intensive Care Units: A Systematic Review. [PDF]

Health Sci Rep
Ahmadizadeh SN, Shamsi H, Izadi N, Dabbagh A, Ebrahimi M, Shahrabi M, Shabani F.   +6 more
europepmc   +1 more source

Exploring individualized crovalimab dosing in PNH through in silico modelling: Potential for improved convenience and cost efficiency

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired haematopoietic stem cell disorder. Crovalimab, a complement C5‐inhibitor, is approved for PNH and can be self‐administered subcutaneously every 4 weeks, offering a more convenient route than intravenous C5‐inhibitors.
Mendy ter Avest, Simon E. Koele, Nicole C. A. J. van de Kar, Saskia M. C. Langemeijer, Rob ter Heine   +4 more
wiley   +1 more source